BergenBio Fundamentale Forhold (BGBIO)

[TekBot]

BERGENBIO PRESENTING AT ARCTIC SECURITIES BIOTECH WEBINAR

Bergen, Norway, 21[st] April 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard
…

Vis børsmeldingen

Godfrey is presenting at the following virtual conference:

Arctic Securities Biotech Webinar, April 22, 2021

Live presentation at 14.05hrs CET

The presentation will be made available on the Company website:
www.bergenbio.com/investors/presentations/

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated in infected organs with an
activation of the signalling pathway leading to suppression of the Type 1
Interferon immune response by infected cells and neighbouring cells, in their
environment. Pre-clinical research studies demonstrate that bemcentinib inhibits
SARS-CoV-2 host cell entry and promotes anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[theroger]

BerGenBio - Bemcentinib preliminary data in COVID-19

[TekBot]

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 23 April 2021; The Board of Directors in BerGenBio ASA (the
“Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the
share option agreements and in accordance with the authorization granted by the
…

Vis børsmeldingen

general meeting on 19 March 2021, resolved to increase the Company’s share
capital by NOK 6,617.30 by issuance of 66,173 new shares. The new shares are
subscribed for by option owners who wishes and are entitled to exercise options
in accordance with the Company’s option scheme. Each option gives a right to
receive one share in the Company. The subscription price is in accordance with
the prevailing options price pursuant to the Company´s option scheme, in average
NOK 17.46 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,788,775.50 consisting of 87,887,755 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Richard Godfrey CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BEMCENTINIB PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRUTAL IMMUNOLOGY 2021

Bergen, Norway, 26 April 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that a poster presentation on
…

Vis børsmeldingen

pre-clinical COVID-19 data has been accepted for presentation at Virtual
Immunology 2021, taking place from 10-15 May 2021. Virtual Immunology 2021 is
the 104[th] annual conference of the American Association of Immunologists.

The presentation illustrates findings from a pre-clinical study conducted by
BerGenBio’s scientific collaborator Professor Wendy Maury, Professor of
Microbiology and Immunology at the University of Iowa, to evaluate AXL as a
therapeutic target for COVID-19 and the potential effect of BerGenBio’s
selective AXL inhibitor bemcentinib, shown to inhibit SARS-CoV-2 infection in in
vitro and in vivo models.

The abstract was deemed to be exceptional by the Virtual Immunology 2021
reviewers so the author, Dana Bohan, a PhD candidate from the University of
Iowa, will receive a 2021 AAI Late Breaking Poster Award.

Poster presentation details at Virtual Immunology 2021 are as follows:

Title: Phosphatidylserine Receptors Enhancement of SARS-CoV-2 Entry: AXL as a
Therapeutic Target for COVID-19

Date: Monday, May 10[th] 2021

Time: 6:30-8:00pm ET

The poster presentation will be made available at BerGenBio’s website
www.bergenbio.com at the date of the presentation.

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities.

Research has also shown that AXL mediates other aggressive diseases including
fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone,
Carina Jurs, Consilium Strategic Communications

bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[theroger]

The abstract was deemed to be exceptional by the Virtual Immunology 2021
reviewers so the author, Dana Bohan, a PhD candidate from the University of
Iowa, will receive a 2021 AAI Late Breaking Poster Award.

[Gajem]

@TekBot

The abstract was deemed to be exceptional by the Virtual Immunology 2021

hvordan denne kursen ikke skyter fart er på meg uforståelig

[Mykle]

@TekBot

The abstract was deemed to be exceptional by the Virtual Immunology 2021
reviewers so the author, Dana Bohan, a PhD candidate from the University of
Iowa, will receive a 2021 AAI Late Breaking Poster Award.

Herlig at forskningen blir anerkjent i de riktige kretsene.

Bergenbio er langt fra ferdige med covid. Det kortsiktige markedet har ikke alltid riktig.

[alfred_e_neuman]

Det kan se ut som at studien «AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery» har fått en ny location i NYC som ikke er registrert på https://clinicaltrials.gov/ct2/show/NCT03965494 enda: https://www.mskcc.org/cancer-care/clinical-trials/20-375

[TekBot]

BERGENBIO TO PRESENT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

Bergen, Norway, 28 April 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that its abstract has been
…

Vis børsmeldingen

accepted for a poster presentation at the American Society of Clinical Oncology
(ASCO) Annual Meeting, taking place online from 4-8 June 2021.

Abstract titles have been announced online at
https://meetings.asco.org/am/abstracts and details of the presentation are
below. Full abstracts will be published on the ASCO website on 19 May 2021.

Title: Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in
combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial
update

Session Title: Lung Cancer - Non-Small Cell Metastatic

Abstract ID: 9110

Date/Time: Friday, June 4, 2021 at 9:00 AM (EDT)

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities.

Research has also shown that AXL mediates other aggressive diseases including
fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Bentus]

Bit for bit faller på plass for BB!

[United2000]







Søk utsteder / ticker

SØK

BerGenBio ASA

Tid28.04.2021, 17:06:44

MeldingsID531479

UtstederIDBGBIO

MarkedOslo Børs

KategoriANNEN INFORMASJONSPLIKTIG REGULATORISK INFORMASJON

Informasjonspliktige opplysninger

AgLagringspliktig melding

Vedlegg



Release.pdf



Del melding









Vis melding i opprinnelig størrelse

BERGENBIO Å PRESENTERE PÅ DET AMERIKANSKE SAMFUNNET FOR KLINISK ONKOLOGI (ASCO) Årsmøte

Bergen, Norge, 28. april 2021? - BerGenBio ASA (OSE: BGBIO), et klinisk stadium biofarmasøytisk selskap som utvikler nye, selektive AXL-kinasehemmere for alvorlig, uoppfylt medisinsk behov, er glade for å kunngjøre at dets sammendrag er blitt akseptert for en plakatpresentasjon på American Society of Clinical Oncology (ASCO) årsmøte, som foregår online fra 4. til 8. juni 2021. Abstrakte titler er kunngjort online på https://meetings.asco.org/am/abstracts og detaljer om presentasjonen er nedenfor . Fullstendige sammendrag vil bli publisert på ASCOs nettside 19. mai 2021. Tittel: Ph I / II-studie av oral selektiv AXL-hemmer bemcentinib (BGB324) i kombinasjon med erlotinib hos pasienter med avansert EGFRm NSCLC: Avslutning på prøveoppdatering Sesjonstitel: Lungekreft - Metastatisk ikke-småcellet abstrakt ID: 9110 Dato / tid: Fredag ​​4. juni 2021 kl. 9:00 (EDT) -Ends- Om AXL AXL kinase er en cellemembranreseptor og en viktig mediator for de biologiske mekanismene som ligger til grunn for livet -truende sykdommer. I COVID-19 har AXL to synergistiske virkningsmekanismer, den virker en ko-reseptor til ACE2, som piggproteinet til SARS-CoV-2-viruset fester og kommer inn i vertscellen, og AXL-uttrykk er oppregulert som fører til undertrykkelse av Type 1 Interferon immunrespons av vertsceller og i deres omgivelser. Forskningsdata bekrefter bemcentinib hemmer SARS-CoV-2 vertscelleinngang og fremmer antiviralt Type I interferonrespons. I kreft har økning i AXL-uttrykk vært knyttet til nøkkelmekanismer for medikamentresistens og immunflukt av tumorceller, noe som fører til aggressiv metastatisk kreft. AXL undertrykker kroppens immunrespons mot svulster og driver behandlingssvikt i mange kreftformer. Høyt AXL-uttrykk definerer en svært dårlig prognosegruppe i de fleste kreftformer. AXL-hemmere, slik som bemcentinib, har derfor potensiell høy verdi som monoterapi og som hjørnesteinen i kreftkombinasjonsbehandling, og adresserer betydelige uoppfylte medisinske behov og flere høyverdige markedsmuligheter. Forskning har også vist at AXL formidler andre aggressive sykdommer, inkludert fibrose. Om Bemcentinib Bemcentinib (tidligere kjent som BGB324), er en potensiell førsteklasses, potent og svært selektiv AXL-hemmer, for tiden i et bredt fase II klinisk utviklingsprogram. Den administreres som en oral kapsel og tas en gang per dag. Pågående kliniske studier undersøker bemcentinib i COVID-19, og flere solide og hematologiske svulster, i kombinasjon med nåværende og nye behandlinger (inkludert immunterapi, målrettet behandling og cellegift), og som et enkelt middel. Bemcentinib målretter mot og binder seg til det intracellulære katalytiske kinasedomenet til AXL-reseptortyrosinkinase og hemmer dets aktivitet. Om BerGenBio ASA BerGenBio er et klinisk stadium biofarmasøytisk selskap med fokus på å utvikle transformative legemidler rettet mot AXL som en potensiell hjørnestein i behandlingen for aggressive sykdommer, inkludert immun-unnvikende, terapiresistente kreftformer. Selskapets proprietære hovedkandidat, bemcentinib, er en potensielt førsteklasses selektiv AXL-hemmer i et bredt fase II klinisk utviklingsprogram med fokus på kombinasjons- og enkeltmiddelterapi i kreft, leukemi og COVID-19. Et førsteklasses funksjonelt blokkerende anti-AXL-antistoff, tilvestamab, gjennomgår klinisk fase I-testing. Parallelt med dette utvikler BerGenBio en ledsagende diagnostisk test for å identifisere pasientpopulasjoner som mest sannsynlig vil ha fordel av AXL-hemming: dette forventes å legge til rette for mer effektive registreringsforsøk som støtter en presisjonsmedisinbasert kommersialiseringsstrategi. BerGenBio er basert i Bergen, Norge med et datterselskap i Oxford, Storbritannia. Selskapet er notert på Oslo Børs (ticker: BGBIO). For mer informasjon, besøk? Www.bergenbio.com Kontakter ir@bergenbio.com Richard Godfrey CEO, BerGenBio ASA Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513 International Media Relations Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700 Media Relations in Norway Jan Petter Stiff, Crux Advisers stiff@crux.no +47 995 13 891 Fremadskuende uttalelser Denne kunngjøringen kan inneholde fremtidsrettede uttalelser, som som sådan ikke er historiske fakta, men er basert på forskjellige forutsetninger, hvorav mange i sin tur er basert på ytterligere forutsetninger. Disse forutsetningene er iboende underlagt betydelige kjente og ukjente risikoer, usikkerheter og andre viktige faktorer. Slike risikoer, usikkerhet, beredskap og andre viktige faktorer kan føre til at faktiske hendelser skiller seg vesentlig fra forventningene som er uttrykt eller antydet i denne kunngjøringen av slike fremtidsrettede uttalelser. Denne informasjonen er underlagt opplysningskravene i henhold til verdipapirhandelloven § 5-12.

Oslo Børs

[vcp]

Her er det bare spørsmål om tid.
Forventer oppstart av 1-3 individuelle fase III studie i løpet av et års tid.

Herunder, i samarbeid med BP

Utover det er jeg veldig spent på effekt på fibrose. - Ettervirkningene av covid i tillegg til øvrig fibrose markedet er stort +.

Jeg tror Bem kommer til å bli godkjent som Covid medisin. Uansett, covid indikasjonen har gitt selskapet og Bem PR som i seg selv burde tilsi høyere kurs imo. Bgbio har markert seg!

Hva tabloidene her hjemme skriver betyr ingen ting. Bem studier har en rekke ganger blitt omtalt i de mest prestisjefylte forskningsmiljøene, det er det som på sikt vil gi uttelling, hva Hegnar og co skriver er mer underholdning

Håper på champis 17mai

[capitan01]

HO omtaler stort sett selskaper som Spetalen er inn og ut av. Undres på koblingen der?

[TekBot]

BerGenBio ASA: Share capital increase

Bergen, Norway, 30 April 2021 - Reference is made to the stock exchange notice
published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 23 April 2021 where
the Company announced that the board of directors of the Company had resolved to
…

Vis børsmeldingen

increase the Company’s share capital in connection with the exercise of options
pursuant to the Company’s share option program. A total of 66,173 options were
exercised and 66,173 new shares were issued at an average subscription price of
NOK 17.46 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company’s share capital
is NOK 8,788,775.50 divided into 87,887,755 shares, each with a nominal value of
NOK 0.10.

-End-

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey

CEO, BerGenBio ASA

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @anon28800809 (497 likes)

@anon28800809

Ny bull artikkel med resultater om bemcentinib i forbindelse med kreftstudier:

2. @vcp (296 likes)

@vcp

Godfrey min gode mann, kom igjen nå.

3. @Fornybar (203 likes)

@Fornybar

https://twitter.com/radforsk/status/1361617595510759428?s=19

Resten av topp 10:

4. @Multiple (192 likes)

5. @Hayen (170 likes)

6. @eiken (146 likes)

7. @Mykle (136 likes)

8. @Direkte (134 likes)

9. @William71 (126 likes)

10. @Tekk (117 likes)

Gratulerer!

[TekBot]

BERGENBIO ASA: INVITATION TO PRESENTATION OF FIRST QUARTER 2021 RESULTS

Bergen, Norway, 5 May 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, will be announcing its results for the first quarter
…

Vis børsmeldingen

2021 on Wednesday 19 May 2021. A webcast presentation by BerGenBio’s senior
management team will take place at 10:00 am CET.

The live webcast link will be available at www.bergenbio.com in the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.

The first quarter report and presentation will be available on the Company’s
website in the Investors/Financial Reports section from 7:00 am CET the same
day.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Kilde

[TekBot]

BerGenBio ASA: Grant of share options

Bergen, Norway, 7 May 2021 - BerGenBio ASA (the “Company”) (OSE:BGBIO) announced
that the Board of Directors has granted share options to employees.

…

Vis børsmeldingen

The annual general meeting in the Company 19 March 2021 approved the share
option program and authorised the board of directors of the Company to issue
shares to the Company’s employees as part of a long-term incentive plan and
share option program.

Options granted under the share option program will vest equally over a three
-year vesting period following the grant and each option, when exercised, will
give the right to acquire one share in the Company at the strike price. Options
granted under the share option program expire eight years after grant date.

A total of 1,379,871 share options, equal to 1.57% of total shares issued in the
Company, were granted at strike price at NOK 28,55 calculated as the volume
weighted average share price over the last two weeks before the grant.

Of the total grant the following were granted to primary insiders (total
holdings of share options following this grant):

Richard Godfrey - CEO: 217,361 (1,759,978)

Rune Skeie - CFO: 54,340 (297,097)

James Barnes - Director of Operations: 64,122 (301,522)

Gro Gausdal - Director of Research: 31,983 (175,359)

Alison Messom - Director of Clinical operations: 61,068 (169,068)

Endre Kjærland - Associate Director of IP and Contracts: 31,052 (161,577)

In total 459,926 share options were granted to primary insiders.

Following this grant a total of 4,890,208 share options are issued, equal to
5.56% of the total shares issued in the Company. Of this, 2,011,507 share
options are vested and 2,848,949 are not vested.

-End-

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey

CEO, BerGenBio ASA

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[eiken]

Her må det vel være noe på gang💪

[vcp]

Hvorfor mener du det @eiken ? dem får hinsides betalt, det skal være sikkert. Jeg forventer at dem leverer deretter resultater.

Er ikke småtterier!

Following this grant a total of 4,890,208 share options are issued, equal to
5.56%

[Matadoren]

Har ikke satt meg inn i opsjonskriteriene i BGBIO, men hvis det er slik at datoen for tildelingen er vilkårlig, må vi anta at primærinsiderne syntes nivået og tidspunktet var gunstig nå. I så fall kan det være positivt for kursen fremover